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Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in females of the              
reproductive age. PCOS is commonly manifested as ovulatory dysfunction, clinical and           
biochemical excess androgen level, and polycystic ovaries. Metabolic sequelae associated          
with PCOS, including insulin resistance (IR), type 2 diabetes (T2DM), obesity and increased             
cardiometabolic risk. The underlying pathology of PCOS is not fully understood with various             
genetic and environmental factors have been proposed. MicroRNAs (miRNAs), are          
endogenously produced, small non-coding, single-stranded RNAs that capable of regulating          
gene expression at the post-transcriptional level. Altered miRNAs expression has been           
associated with various disorders, including T2DM, IR, lipid disorder, infertility,          
atherosclerosis, endometriosis, and cancer. 
Given that PCOS also present with similar features, there is an increasing interest to              
investigate the role of miRNAs in the diagnosis and management of PCOS. In recent years,               
studies have demonstrated that miRNAs are present in various body fluids, including            
follicular fluid of women with PCOS. Therefore, it may act as a potential biomarker and               
could serve as a novel therapeutic target for the diagnosis and treatment of PCOS. This               
review aims to summarise the up to date research on the relation between miRNAs and               
PCOS and explore its potential role in the diagnosis and the management of PCOS. 
Keywords: ​polycystic ovary syndrome, PCOS, microRNA, miRNAs, biomarkers, T2DM,         
infertility, follicular development, lipid metabolism, hyperandrogenism. 
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Introduction  
Polycystic ovary syndrome (PCOS) is the most prevalent endocrine disorder in women of             
reproductive age with a prevalence of approximately 10 - 20 % (1). It is a heterogeneous                
disorder with different phenotypes and characterised by clinical and biochemical evidence           
of hyperandrogenism, menstrual irregularities and polycystic ovarian morphology (2). The          
Rotterdam 2003 criteria are currently acceptable for the diagnosis of PCOS, where two out              
of the following three criteria are satisfied: anovulation/oligoovulation, clinical and          
biochemical sign of hyperandrogenism and polycystic ovaries, after excluding other          
aetiologies such as congenital adrenal hyperplasia and androgen-secreting tumours (3).          
PCOS also has its metabolic consequences such as insulin resistance (IR), hyperlipidaemia,            
obesity, oxidative stress, type 2 diabetes mellitus (T2DM) and increased risk of            
cardiovascular disease (CVD) (4). It also linked to an increase in pregnancy-related            
complications such as gestational diabetes, preterm birth, antepartum haemorrhage and          
pregnancy-induced hypertension (5). The aetiology of PCOS is unclear; however,          
environmental and genetic factors have been proposed as a potential cause of PCOS (6). In               
recent years, the association between regulatory miRNAs and various diseases has been an             
area of intensive research.  
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MicroRNAs (miRNAs) are a new class of endogenous, non-coding, single-stranded RNA           
molecules with 20-25 nucleotides that regulate post-transcriptional gene expression by          
binding to the 3' untranslated location of the target messenger RNA (mRNA), thus, lead to               
the inhibition of mRNA expression and block post-transcriptional protein translation (7, 8).            
miRNAs are widely presented in the human body and can be isolated from urine, plasma,               
semen and saliva or might be encapsulated in microvesicles (9-12). They have also been              
expressed in different organs, including the liver, adipose tissue and muscle (13)​—figure 1​.             
A piece of accumulative evidence has shown that miRNAs regulate various critical regulatory             
biological functions including cell growth and development, apoptosis, metabolism, stress          
response and hematopoietic differentiation (8, 14). A single miRNA has the potential to             
modulate the function and expression of various target genes, and amplification or            
inhibition of miRNA signal via the regulatory feedback mechanism may drive to a significant              
alteration of miRNA expression which contributes to different disease including ovarian           
cancer, endometriosis, cardiovascular disease and inadequate ovarian response (15-17).         
There is also growing evidence demonstrating the influence of miRNAs in the pathogenesis             
of diabetes mellitus, and they could potentially be a novel biomarker for diabetes (18).              
There is also data showing differential expression of circulating miRNAs in women with and              
without PCOS (19). Therefore, it has been proposed to be useful as a diagnostic biomarker               
or a potential therapeutic target for PCOS. However, our understanding of the exact             
relationship between miRNAs and PCOS is still preliminary, and the potential role of miRNAs              
in the diagnosis and the management of PCOS is yet to be clarified.  
4 
 
In line with these considerations, this review was conducted to summarise the existing data              
to establish the potential role of some miRNAs as a potential clinical biomarker and              





 miRNAs as a potential novel clinical biomarker for PCOS  
 ​miRNAs and ovarian dysfunction in PCOS  
In recent years, many attempts have been made trying to understand the exact mechanism              
of anovulation and abnormal folliculogenesis in women with PCOS. As a result, Increased             
plasm level of luteinising hormone (LH) and androgen with normal or low levels of the               
follicular stimulating hormone (FSH) has been suggested (20). Furthermore, abnormal          
steroidogenesis, excessive expression of anti-Mullerian hormone (AMH) and impaired         
follicular apoptosis have also been reported (21). 
MiRNAs increase expression of proliferating cell nuclear antigen protein (PCNA), a marker             
of proliferation (22). They also regulate follicular granulosa cells (FGCs) by modulating            
expression at the target organ (23), and they are differentially expressed amongst different             
follicular sizes during follicular atresia (24, 25). Among the most common miRNAs altered             
during follicular atresia is miR-1275, which is also known to regulate FGCs apoptosis (26). In               
several human studies, a vast array of miRNAs has been explored to determine their              
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functions in follicular atresia and FGCs apoptosis. The miR-15a has been found promotes             
steroidogenesis by increasing progesterone and testosterone synthesis (27). ​Figure 1​. The           
miR-23a and miR-27a stimulate FGCs apoptosis by targeting SMAD5 protein, while miR-93            
promotes proliferation by targeting cyclin-dependent kinase inhibitor 1A (CDKN1A) protein          
(28-30). The Let-7 family of miRNAs which regulates cell proliferation, differentiation and            
tumour suppression was highly expressed among animal species (31). Further study has            
reported the transforming growth factorβ receptor (TGFBR), and the mitogenic-activated           
protein kinase 1 (MAP3K1) as a potential target for miR-let-7 and the suppression of              
MAP3K1 induces apoptosis (32). The miR-Let-7c, miR-23A, miR-27a and miR-22-3p were also            
expressed in patients with premature ovarian failure compared to the healthy population            
(33). Most recent studies have shown abnormal expression of miRNAs are often seen with              
follicular maturation in PCOS (14, 34, 35).  
In a study of rat model with PCOS exposed to dihydrotestosterone (DHT) found that 72               
miRNA was upregulated and the 17 miRNA were downregulated in DHT- exposed ovaries             
compared to control ovaries, with miR-32, miR-21, miR-182, miR-183, miR-184 and miR-96            
were primarily downregulated (36). Furthermore, most of these miRNAs were extensively           
expressed in granulosa cells (GCs) of the ovary compared to other ovarian cells. For              
example, miRNA-376 associated with primordial follicular development and it influences          
GCs proliferation through miRNA-376a, which directly binds to the targeted location 3'UTR            
mRNA of the PCNA (37). ​Table1​. However, further study showed that increased expression             
of miRNA-143 inhibits primordial folliculogenesis by suppressing GCs proliferation (38).          
miR-224 also has been expressed in GCs of the ovaries; it induces GCs proliferation via               
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transforming growth factor-β (TGF-β), and induction of GCs proliferation mediated          
through TGF-β1 receptor facilitated by miR-224 upregulation (39). 
Furthermore, miR-145 found to target the transforming growth factor β 2 (TGF-β2)            
receptor and hence initiates and maintains the primordial follicular development (34).           
miR-224 has also been recognised targeting Pentraxin 3 (PTX3), a protein linked to cumulus              
expansion (40). In PCOS, a miRNA-PTX3 expression associated with the fertilisation process            
and therefore; it could potentially be used as a biomarker to assess the quality of oocyte                
(41). miR-182 and miR-15a play an essential role in the physiology of GCs of the ovaries by                 
regulating steroidogenesis, induce proliferation and apoptosis; however, their levels were          
significantly low in the ovarian cell of PCOS rat model (27, 36).​Figure 1​. Thus, the expression                
of these miRNAs might influence the timing of development and maturation of oocyte by              
targeting the gonadotropin-releasing hormone (GnRH) pathway (42). Therefore, these         
findings outlined the importance of miRNAs for controlling the process of proliferation and             
apoptosis of the ovarian GCs and subsequently folliculogenesis, which could be a potential             
target to assess for ovulation in PCOS.  
miRNAs and follicular fluid (FF) in PCOS 
Follicular fluid (FF) provides a suitable environment for oocyte development and           
maturation. Its proximity to the oocytes allows for efficient exchange of components            
between blood, granulosa and theca cells (TCs) (43). Additionally, FF contains various            
hormones such as androgen, oestrogen, LH, FSH, growth hormone, TGF-β, anti-Mullerian           
hormone (AMH), activin and metabolic and secretory products of the oocyte (44). The             
collection of FF is relatively easy during harvesting oocyte for assisted fertilisation, i.e.             
7 
 
in-vitro fertilisation (IVF). Thus, it serves as a less invasive procedure for obtaining miRNAs              
and to assessment for fertility outcomes. 
Furthermore, analysing FF compositions may also indicate the quality of oocyte and the             
functional status of GCs and CTs (45). The recent discovery of miRNAs in the human body                
has inspired researchers to study their functions in various biological processes. In a study              
by Butler et al., has detected 176 miRNAs, of which 29 were differentially expressed in the                
FF of women with PCOS and normal control women (46). As a result, miR-382-5p was               
correlated positively with age and free androgen index (FAI), miR-199b-5p linked with AMH             
and miR-127-3p was associated with insulin resistance, and further analysis revealed 12            
miRNAs correlated with reproductive pathways (46). In the previous study by Sathyapalan et             
al. has described the potential diagnostic significance of miR-93 as a novel biomarker for the               
diagnosis of PCOS after it was found relatively higher in women with PCOS compared to               
women without PCOS (47). A further study discovered over 100 differentially expressed            
miRNAs that potentially regulate steroidogenesis in FF of women with PCOS with two             
miRNAs (miR-132 and miR-320) has significantly reduced in FF of PCOS women (43). 
Moreover, downregulation of miR-29a, miR-24-3p and miR-574-3p were reported in women           
with PCOS compared with women without PCOS, and serum levels of total and free              
androgen were correlated positively with miR-518f-3p in subjects with PCOS (48). These            
alterations in miRNAs profiles might facilitate the phenotypic stratification in women with            
PCOS. The combination of miR-30a, Let-7b and miR-140 expression has a sensitivity of 70 %               
and specificity of over 83 % in discriminating between the normal ovarian reserve and PCOS,               
particularly during assisted fertilisation (49). Thus, this could potentially provide a novel            
biomarker to predict outcomes and to facilitate a personalised level of medical care for              
8 
 
women with PCOS. In a study in which 27 miRNAs were differentially expressed in women               
with PCOS, miR-92a and miR-92b were significantly downregulated (50). Another study           
reported expression of 235 miRNAs of which 29 miRNAs were differentially expressed in             
PCOS and control group, but miR-32, miR-34c, miR-135a, miR-18b and miR-9 have            
demonstrated a significantly increased expression in PCOS group (51). To sum, these            
findings confirm that there are differentially expressed miRNAs in the FF of women with              
PCOS. Thus, it is imperative to propose that examining different miRNAs present in the FF of                
women with PCOS may potentially provide a novel biomarker for the diagnosis of PCOS.              
Furthermore, it might aid with the classification of different phenotypes of PCOS. Moreover,             
the environment of FF also contains various hormones and metabolic products; adjusting            
this microenvironment could improve the reproductive outcomes in PCOS.  
 
 ​miRNAs and fertility in PCOS  
The role of miRNAs in the level of fertility has recently been studied extensively, particularly               
after the discovery of Dicer 1 a ribonuclease III enzyme essential for miRNAs production              
(52). The Knock-out of this enzyme in mice resulted in infertility by reducing the rate of                
ovulation and mitogenic progression due to defective spindle arrangement in an animal            
model (53). However, in a human study, blastocytes extraction from women with PCOS has              
shown significantly low expression of hsa-miR-19a, hsa-miR-19b, hsa-miR-24 and         
hsa-miR-93 compared to healthy control. ​Figure 1​. Furthermore, heatmap analysis for the            
expression of these miRNAs showed expression of miR-19a and its target gene ARIH2             
(essential for cell differentiation) has significantly upregulated in women with PCOS           
compared to women without PCOS. 
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Similarly, NFAT5 and KHSRP genes targeted by miR-24 and encoding transcriptional and            
decaying factors for miRNAs were both upregulated in women with PCOS with a significant              
decrease in miR-24 expression (54). miR-290-295 have a pivotal role in the embryogenesis             
as demonstrated in a cluster of mutant mouse embryos, in the miR-290-295 deficient male              
mutant mice the fertility was restored later during their development, unlike the female             
mutant mice which remained infertile, indicating the role of defective miR-290-295 on the             
GCs (55). Moreover, transfection of GCs with miR-27a, miR-322 and Let-7c inhibitor has led              
to increased oocyte follicular maturation of mouse ovaries (56). 
Maternal age is another major factor for infertility. In a study, various differentially              
expressed miRNAs were expressed in women above the age of 40s compared to women in               
their 20s and miR-93 was exceptionally expressed only in blastocytes with chromosomal            
abnormalities in older women (57), this is a clear indication that maternal ageing is not only                
a risk factor for infertility but also associated with modification of miRNAs profiles (58).  
miRNAs and steroidogenesis in PCOS 
The reproductive cycle of the ovaries is coordinated by hormones released from the             
hypothalamic-pituitary-ovarian axis. Alterations in this pathway lead to abnormal hormone          
production, which has been observed in women with PCOS (59). Excess androgen level is a               
common presenting feature in PCOS, and it may be due to overstimulation of the ovarian               
TCs by LH to synthesise androgen or due to defects of androgen receptors at the target                
organs level (60). The majority of testosterone is bound to SHBG and albumin with the only                
small fraction is circulating freely as bioactive testosterone. Women with PCOS have low             
SHBG levels which increase the bioavailable testosterone level (61). There is a considerable             
amount of evidence proposed that excess androgen is the main drive for ovulatory and              
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metabolic dysfunction seen in PCOS (62). It facilitates visceral adiposity and IR with             
subsequent increase in ovarian androgen production and commonly present as hirsutism,           
acne and menstrual disturbances (63). Even though high androgen is a pathological feature             
of PCOS, recent evidence suggested that testosterone, dihydrotestosterone (DHT) and          
androstenedione (A4) play a vital role on ovulation by facilitating the follicular development             
and maturation (64). Androgen hormones apply their function by binding into the androgen             
receptor (AR) at their target tissues, and increased expression of AR has been shown in               
women with PCOS (65). AR can be expressed in various cells; however, it is predominantly               
found in the granulosa cells (GCs) of the growing ovarian follicle (66). The effects of miRNAs                
on steroidogenesis from the ovarian cells have been explored across a variety of the living               
animal species. 
The transfection of miR-24 resulted in a decreased level of oestradiol secretion. Conversely,             
overexpression of miR-520c-3p, miR-132 and miR-320 derived to increased oestradiol          
release and the transfection of miR-483-5p, miR-24 and miR-193b associated with           
decreased progesterone secretion (43). miR-513a-3p was negatively correlated with the          
luteinising hormone and gonadotropin receptor (LHCGR) (67). Furthermore, miR-107         
positively associated with testosterone secretion; on the other hand, miR-146a has           
significantly reduced testosterone secretion (19, 68). miR-103, miR-155 and miR-21 were           
also shown to correlate positively with free testosterone levels in women with PCOS (69).              
miR-320, miR-518 and miR-29a were positively associated with an increased level of serum             
testosterone, ​Figure 1​. while miR-151 was negatively linked to serum testosterone (70).            
Recently, a study suggested that miR-155 and miR-29a are negatively associated with serum             
A4 in women with PCOS (71).  
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The synthesis of steroid hormones depends on different genes which regulate the signalling             
pathways, androgen metabolism and lipid transport. At the same time, LH and FSH control              
the androgen production and the testosterone conversion respectively by acting directly on            
the GCs of the ovarian follicles. Key enzymes and genes such as CYP19, CYP11A, StAR, CYP17                
CYP19A1 and 3-b HSD are involved in the steroid hormone production, and oestrogen             
synthesis depends on aromatase enzyme which regulated by CYP19 A1 gene (60). 
Overexpression of miR-181a and miR-378 downregulate aromatase enzyme and hence          
reduce oestrogen synthesis in GCs (72-74). Inversely, many miRNAs have shown to correlate             
positively with oestradiol synthesis. For instance, overexpression of miR-133b increase          
oestradiol synthesis with a simultaneous increase in CYP19A1 in the GCs of FSH-stimulated             
mice by targeting forkhead box L2 (fox12) (75, 76).​Figure1. On the other hand,             
overexpression of miR-224 derived to increased oestrogen release by targeting SMAD4 of            
mouse GCs (39). miR-193a-5p and miR-199a-3p are negatively correlated with testosterone           
level and positively linked with SHBG and oestradiol in women with PCOS (69). In-depth              
understanding of the correlation between miRNAs and the synthesis of steroid hormones            
will potentially aid the diagnosis of PCOS and will help predict its metabolic consequences.  
miRNAs and the metabolic consequences of the PCOS  
miRNAs and insulin resistance in PCOS 
Insulin resistance (IR) is a common feature of PCOS with a prevalence of approximately 70 %                
of the cases have IR (77). It plays a significant role in the pathogenesis of PCOS and                 
associated with increased risk of metabolic syndrome, impaired glucose tolerance,          
dyslipidaemia, T2DM and cardiovascular disorders (78). Hyperinsulinemia is capable of          
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stimulating steroidogenesis and increase ovarian androgen secretion from the theca cells           
(TCs) mediated by the insulin growth factor-1 (IGF-1) receptors; high insulin level also             
potentiates LH effect on TCs to cause excess androgen (77). ​Figure2. IR is contributing to               
high androgen level by increased activity of CYP17 enzyme with synergetic action of LH on               
TCs. It increases cyclic adenosine monophosphate (cAMP) concentration, reduces SHBG and           
subsequent increase the free testosterone levels (79, 80). In an animal study by Ling et al.,                
3T3-L1 adipocyte cells were transformed into IR cells by administering high levels of insulin              
and glucose after a significant increase in expression of miR-320 (81). However, insulin             
sensitivity was restored shortly after treatment with anti-miR-320 oligos which alleviated IR            
by upregulating glucose transporter 4 (GLUT4) expression and improving insulin-mediated          
glucose uptake (82). miR-320 has been confirmed to exist in abundance in FF of women               
with PCOS, advocating that it could be a target for enhancing insulin sensitivity (43, 81). A                
study found that expression of miR-194,miR-193b and miR-122 was upregulated in women            
with PCOS particularly those with impaired glucose by targeting different signalling           
pathways, including insulin signalling pathway, glycometabolism pathway and follicular         
development pathway (83). The role of miRNAs in regulating GLUT4 has been recently             
investigated. Expression of miR-93 showed a strong correlation between GLUT4 and IR in             
adipose tissue of women with PCOS, and activating miR-93 downregulates GLUT4 by            
targeting GLUT4 3'UTR; however, suppressing miR-93 activity facilitated GLUT4 expression          
(84). Overexpression of miR-33b-5p was detected in the ovarian cells of PCOS rat model              
with IR, and it was negatively correlated with GLUT4, sterol regulatory element-binding            
protein 1 (SREBF1) and high mobility group A2 (HMGA2) expression. These findings            
demonstrated that miR-33b-5p plays a vital role in the development of IR in patients with               
PCOS through inhibition of GLUT4 expression. Additionally, it also has the potential to adjust              
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the expression of various protein cascades in insulin signalling pathways (85). For example,             
the expression of miR-143 inhibits insulin-regulated AKT-kinase activity a key enzyme in the             
insulin signalling pathway (86). Many miRNAs such as miR-126, miR-29, miR-1 and miR-19a             
have been proposed to regulate PI3K, which mediate insulin-facilitated glucose uptake           
(86).​Figure2​. 
Furthermore, the miR-483-5p reduces IR and facilitates cumulous cell proliferation by           
activating PI3K/AKT (87). In general, the expression of miRNAs plays an essential role in              
regulating glucose metabolism, insulin signalling pathway and the pathogenesis of IR in            
women with PCOS by determining the expression of GLUT4, proteins and enzymes of the              
glucose metabolism.  
miRNAs and lipid disorders in PCOS 
PCOS also associated with dyslipidaemia with around 70 % of women with PCOS have some               
sort of abnormal lipid profiles manifesting as high triglycerides, elevated low-density           
lipoprotein cholesterol (LDL-C) and decreased high-density lipoprotein cholesterol (HDL-C)         
levels (88, 89). These high lipid profiles are atherogenic and strongly associated with a high               
risk of CVD; therefore, women with PCOS are at increased risk of cardiovascular morbidities              
(90). Obesity also has a detrimental effect on the metabolic aspects of PCOS with              
approximately around 88 % of women with PCOS, either overweight or obese (89).  
It is well established that miRNAs have significant effects on lipid metabolism and             
cholesterol homeostasis. The miR-33 has been shown to target adenosine triphosphate           
(ATP) binding cascade transporter A1 (ABCA1) an important regulator which increases the            
level of HDL- C and facilitates cholesterol disposal by the liver (91-93). Moreover, miR-33              
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has also shown to regulates ABCG1, cholesterol 7-α hydroxylase (CYP7A1) and ABCB11            
genes involved in reverse cholesterol transport (RCT) (94, 95). ​Figure 1. The miR-122 and              
miR-30c play an essential role in controlling LDL-C by adjusting the cholesterol biosynthesis             
and VLDL-C secretion. Even more, they decrease Apo B lipoproteins by targeting the             
microsomal triglyceride transferase protein (MTP) (96). Targeting miR-122 in an animal           
model has demonstrated a significant reduction in cholesterol and triglyceride levels.           
However, this effect was overshadowed by the increased risk of hepatic cancer and fibrosis              
associated with miR-122 deletion (97)​—figure 1​. Besides, in animal model inhibition of            
miR-33 has shown to modify VLDL-C and triglyceride biosynthesis, and anti-miR-33 has            
significantly reduced VLDL-C and triglyceride (98). Expression of miR-33 shown to has a             
control on ABCA1 and ABCG1 through activation of SREBP-2, and inhibition of miR-33             
increases the hepatic expression of ABCA1 and subsequently increases HDL levels (91, 92).             
Furthermore, several miRNAs have demonstrated control over LDL-C metabolism. For          
instance, inhibition of miR-128-1, miR-185 and miR-148a has markedly reduced LDL-C levels            
(99-101). Furthermore, the expression of miR-148a has shown to alter the blood levels of              
LDL-C by targeting 3’UTR of the LDLR and other genes vital for lipid metabolisms such as                
ABCA1, AMPK, PGC1α and SIK1. Additionally, miR-148a expression increases HDL-C levels           
by regulating ABCA1 expression in the liver (99, 100, 102). miR-130 and miR-143 are              
strongly linked to adipogenesis, the expression of miR-143 is upregulated in the obese             
animal model, and inhibition of miR-143 reduced insulin activated AKT (103). Moreover,            
overexpression of miR-130a inhibits adipocytes differentiation by suppressing PPAR-γ         
activity (104). Conversely, expression of miR-375 shown to induce adipogenesis by           
increasing PPAR-γ, C/EBP-α and promoting 3T3-L1 (105). A study found that the            
expression of miR-103 and miR-27b is significantly higher in women with PCOS compared to              
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women without PCOS (21). The expression of miR-23a and miR-23b has been positively             
correlated with body mass index (BMI) despite its lower level in women with PCOS (106).               
However, on the other hand, miR-199a-5p and miR-199a-3p were negatively correlated with            
waist/hip ratio and BMI (69). These findings indicated the strong association between            
miRNAs, obesity and dyslipidaemia and laid down its potentiality as a therapeutic target in              
the management of the metabolic aspects of PCOS.  
miRNAs as a potential therapeutic target in PCOS  
According to the current guidelines, strategies for management of PCOS are merely focused             
on alleviating symptoms and improve the prognostic outcomes. Various pharmacological          
approaches are used including insulin sensitising agents which enhance the insulin           
sensitivity and subsequently reduce IR, fertility treatment such as letrozole and clomiphene            
citrate to induce ovulation, anti-androgen therapies for the treatment of high           
androgen-related symptoms (i.e. hirsutism and acne) and oral contraceptives to regulate the            
menstrual cycle. Insulin resistance (IR) is a main pathological feature of PCOS and improving              
insulin sensitivity might facilitate glucose metabolism, reduces androgen levels and          
augments fertility.  
Metformin is a drug that has been used for decades in the management of PCOS. It                
improves insulin sensitivity, impaired glucose tolerance (IGT) and consequently reduces          
androgen levels in women with PCOS (107, 108). Even though, its effect on induction of               
ovulation and improving fertility in women with PCOS still debatable, there is a considerable              
amount of evidence showed it has a significant impact in improving the rate of ovulation               
and the outcome of pregnancy (109-112). Recently, miRNAs have also attracted           
considerable interest as a potential target for therapeutic and prognosis of PCOS. 
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In a study; metformin administration decreased the expression of the pancreatic cancer             
stem cells (CSC) markers by increases the expression of miR-26a (113). Furthermore,            
metformin also downregulates miR-221 and miR-222 that promote intimal thickness in           
patients with T2DM (114).​Figure1​. Even more, evidence suggests that treatment with           
metformin upregulates DICER1 and enhances the stability of DICER1 mRNA and permitting            
DICER1 to accumulate, which may offer a new therapeutic approach for age-related health             
problems (115). Recently, the incretins-based treatment, including glucagon-like peptide 1          
agonist receptor agonist (GLP-1 RA) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have           
inspired researcher to examine its potential benefits for managing the metabolic aspect of             
PCOS. A recent study has demonstrated that overexpression of miR-155-5p and miR-33            
stimulate insulin secretion by increasing the expression of GLP-1 on the β-cells of the              
pancreas (116). On the other hand, miR-197, miR-6356, miR-1197-3p, miR-875-5P and           
miR-6763 inhibit the incretin expression and therefore, reduce insulin secretion (117).           
GLP-1 RA increases the expression of miR-27a, miR-192, miR-132 but reduces miR-375 and             
miR-23 expression, which has a significant glycaemic effect by stimulating insulin secretion            
and thus, lowering blood glucose (117). Therefore, with the currently growing evidence on             
incretins-based therapies for T2DM management, and the newly emerging evidence about           
its influence on miRNAs expression. The incretins-miRNAs pathway might be a potential            
therapeutic target for PCOS; however, it is still a fertile ground for further scientific              
research. 
The metabolic comorbidities associated with PCOS are mostly due to the vicious cycle              
between IR and high androgen levels. Therefore, the treatment approach targeting excess            
androgen levels can significantly improve the clinical manifestations associated with PCOS.           
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Anti-androgen therapies are used to treat symptoms of high androgen levels, such as             
hirsutism and acne. miR-212 and miR-199 have shown to modulate androgen receptor (AR)             
and enhances its production by targeting CYP19A1(118). Furthermore, miR-155 is          
correlated negatively with A4 concentration (71). miR-838-p3, miR-9563a-p3 and         
miR-9563-p5 are targeting ACO32, GDL73 and MFPA a transcript that regulate the            
long-chain fatty acid synthesis, lipid transport and metabolism (119). 
Additionally, miR-27b also plays an essential role in regulating fatty acid and cholesterol             
metabolism (102), and miR-155 has a significant role in monitoring the effectiveness of             
anti-androgen therapy (71). These potential effects of miRNAs on androgen hormone might            
have a substantial role in improving PCOS related symptoms by augmenting anti-androgen            
treatments. 
Conclusion and future direction  
In conclusion, the diagnosis and the treatment of PCOS have emerged as one of the most                
significant challenges faced by clinicians and healthcare professionals. Over the last few            
years, several promising studies have been focused on the characterisation and           
identification of various miRNAs. Some PCOS-associated miRNAs are abundantly expressed          
in the ovaries, skeletal muscles, adipose tissues, and the pancreas. They regulate the             
follicular development and maturation, steroid hormone synthesis, adipogenesis, insulin         
signalling pathway. Given all these, miRNAs could potentially be clinical biomarkers for the             
diagnosis of PCOS and a therapeutic target in the treatment of PCOS. The potential miRNAs               
based therapeutic options will provide a new horizon and a compelling alternative for the              
treatment of PCOS and its related metabolic complications.  
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Limitation of miRNAs applied in clinical practice 
There are apparent promises, hopes, enthusiasm and significant efforts to promote           
miRNAs-based products. However, despite the advances in the diagnostic field and the            
thousands of scientific research in this area, miRNAs as a potential diagnostic tool is still in                
their infancy. On the other hands, despite the potentials, miRNAs-based therapeutics are            
yet to be developed. Therefore, the development of commercially available miRNAs-based           
diagnostics and therapeutic tools is a long way to go. 
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Table1:​ miRNAs detected in PCOS and their proposed functions 
miRNAs Detected in tissues Proposed functions       
Detected in PCOS                             References  
miR-376 GCs Increase GCs proliferation by        
Increased expression in PCOS                (37) 
                                                                                                  Increase expression of PCNA   
miR-224 GCs ​Increase fertilisation by increase         
Increased expression in PCOS                (41)  
                                                                                                 PTX-3 expression in GCs   
miR-182 /miR-15a GCs Regulate steroidogenesis and promote         
Decreased expression in PCOS               (27, 36) 
                                                                                                 ​GCs proliferation and apoptosis  
miR-132/miR-320 ​GCs Regulate steroidogenesis     
Decreased expression in PCOS                (43) 
​miR-320 Adipocytes cells Increase IR by downregulate GLUT4          
Increased expression in PCOS                  (81)  
miR-33b-5p ​GCs Negatively correlate with GLUT4,        
Increased expression in PCOS                  (85)  
                                                                                                 ​SREBF1 and HMGA2 and promote IR 
miR-27b Blood ​Induce adipogenesis by increasing          
Increased expression in PCOS                  (21) 
                                                                                                 PPAR-γ and C/EBP-α  
miR-103/ miR-155 ​Blood/GCs Induce progesterone release and        
Increased expression in PCOS                  (69) 
inhibit oestradiol release    
and correlate with increased  
 
testosterone  
miR-155 GCs Inhibit testosterone release by inhibiting          
Increased expression in PCOS                  (71) 
                                                                                                 PCNA  
GCs; granulosa cells​, PCNA; ​proliferating cell nuclear antigen protein, ​PTX-3; ​Pentraxin 3, ​GLUT4;              
Glucose transporter 4, ​SREBF1; sterol regulatory element-binding protein,​HMGA2; high mobility          
group A2​,IR; ​insulin resistance, ​PPAR-γ; ​peroxisome proliferator activating factor-γ, C/EBP-α;          




Figure 1: The expression of miRNAs in different organs and their cross talk in regulating               
follicular development, follicular maturation, steroidogenesis, glucose metabolism, insulin        
















Figure2: ​Role of miRNAs in the insulin signalling pathway and insulin resistance.  
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